344 related articles for article (PubMed ID: 17515455)
1. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia.
Rana S; Karumanchi SA; Levine RJ; Venkatesha S; Rauh-Hain JA; Tamez H; Thadhani R
Hypertension; 2007 Jul; 50(1):137-42. PubMed ID: 17515455
[TBL] [Abstract][Full Text] [Related]
2. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.
Baumann MU; Bersinger NA; Mohaupt MG; Raio L; Gerber S; Surbek DV
Am J Obstet Gynecol; 2008 Sep; 199(3):266.e1-6. PubMed ID: 18771978
[TBL] [Abstract][Full Text] [Related]
3. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
[TBL] [Abstract][Full Text] [Related]
4. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
Govender N; Naicker T; Rajakumar A; Moodley J
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
[TBL] [Abstract][Full Text] [Related]
5. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women.
Moore Simas TA; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Maynard SE
J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1038-48. PubMed ID: 24066977
[TBL] [Abstract][Full Text] [Related]
6. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE
Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463
[TBL] [Abstract][Full Text] [Related]
7. Circulating Angiogenic Factors and the Risk of Preeclampsia in Systemic Lupus Erythematosus Pregnancies.
Leaños-Miranda A; Campos-Galicia I; Berumen-Lechuga MG; Molina-Pérez CJ; García-Paleta Y; Isordia-Salas I; Ramírez-Valenzuela KL
J Rheumatol; 2015 Jul; 42(7):1141-9. PubMed ID: 25979720
[TBL] [Abstract][Full Text] [Related]
8. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.
Kusanovic JP; Romero R; Chaiworapongsa T; Erez O; Mittal P; Vaisbuch E; Mazaki-Tovi S; Gotsch F; Edwin SS; Gomez R; Yeo L; Conde-Agudelo A; Hassan SS
J Matern Fetal Neonatal Med; 2009 Nov; 22(11):1021-38. PubMed ID: 19900040
[TBL] [Abstract][Full Text] [Related]
9. Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria.
Ohkuchi A; Hirashima C; Matsubara S; Suzuki H; Takahashi K; Usui R; Suzuki M
Hypertens Pregnancy; 2009 Feb; 28(1):95-108. PubMed ID: 19165674
[TBL] [Abstract][Full Text] [Related]
10. Soluble endoglin for the prediction of preeclampsia in a high risk cohort.
Maynard SE; Moore Simas TA; Bur L; Crawford SL; Solitro MJ; Meyer BA
Hypertens Pregnancy; 2010; 29(3):330-41. PubMed ID: 20670156
[TBL] [Abstract][Full Text] [Related]
11. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?
Myatt L; Clifton RG; Roberts JM; Spong CY; Wapner RJ; Thorp JM; Mercer BM; Peaceman AM; Ramin SM; Carpenter MW; Sciscione A; Tolosa JE; Saade G; Sorokin Y; Anderson GD;
BJOG; 2013 Sep; 120(10):1183-91. PubMed ID: 23331974
[TBL] [Abstract][Full Text] [Related]
12. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.
Chaiworapongsa T; Romero R; Korzeniewski SJ; Kusanovic JP; Soto E; Lam J; Dong Z; Than NG; Yeo L; Hernandez-Andrade E; Conde-Agudelo A; Hassan SS
Am J Obstet Gynecol; 2013 Apr; 208(4):287.e1-287.e15. PubMed ID: 23333542
[TBL] [Abstract][Full Text] [Related]
13. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
Powers RW; Jeyabalan A; Clifton RG; Van Dorsten P; Hauth JC; Klebanoff MA; Lindheimer MD; Sibai B; Landon M; Miodovnik M;
PLoS One; 2010 Oct; 5(10):e13263. PubMed ID: 20948996
[TBL] [Abstract][Full Text] [Related]
14. Maternal, gestational and neonatal characteristics and maternal angiogenic factors in normotensive pregnancies.
Staff AC; Harsem NK; Braekke K; Hyer M; Hoover RN; Troisi R
Eur J Obstet Gynecol Reprod Biol; 2009 Mar; 143(1):29-33. PubMed ID: 19135290
[TBL] [Abstract][Full Text] [Related]
15. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
[TBL] [Abstract][Full Text] [Related]
16. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia.
Masuyama H; Nakatsukasa H; Takamoto N; Hiramatsu Y
J Clin Endocrinol Metab; 2007 Jul; 92(7):2672-9. PubMed ID: 17426083
[TBL] [Abstract][Full Text] [Related]
17. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia.
Rana S; Cerdeira AS; Wenger J; Salahuddin S; Lim KH; Ralston SJ; Thadhani RI; Karumanchi SA
PLoS One; 2012; 7(10):e48259. PubMed ID: 23110221
[TBL] [Abstract][Full Text] [Related]
18. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.
Erez O; Romero R; Espinoza J; Fu W; Todem D; Kusanovic JP; Gotsch F; Edwin S; Nien JK; Chaiworapongsa T; Mittal P; Mazaki-Tovi S; Than NG; Gomez R; Hassan SS
J Matern Fetal Neonatal Med; 2008 May; 21(5):279-87. PubMed ID: 18446652
[TBL] [Abstract][Full Text] [Related]
19. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors.
Lim JH; Kim SY; Park SY; Yang JH; Kim MY; Ryu HM
Obstet Gynecol; 2008 Jun; 111(6):1403-9. PubMed ID: 18515525
[TBL] [Abstract][Full Text] [Related]
20. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion.
Stepan H; Geipel A; Schwarz F; Krämer T; Wessel N; Faber R
Am J Obstet Gynecol; 2008 Feb; 198(2):175.e1-6. PubMed ID: 18226617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
